Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
A Phase I/II trial previously revealed variable anti-tumor efficacy of the PARP inhibitor niraparib in combination with the PD-1 inhibitor pembrolizumab in platinum-resistant ovarian cancer patients. Here, the authors perform an integrated genomic and immunomics analysis of tumor samples from the sa...
Guardado en:
Autores principales: | Anniina Färkkilä, Doga C. Gulhan, Julia Casado, Connor A. Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro, Yinghui Zhou, Julie R. Graham, Bruce J. Dezube, Pamela Munster, Sandro Santagata, Elizabeth Garcia, Scott Rodig, Ana Lako, Dipanjan Chowdhury, Geoffrey I. Shapiro, Ursula A. Matulonis, Peter J. Park, Sampsa Hautaniemi, Peter K. Sorger, Elizabeth M. Swisher, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bd4459e944254dc4845c521cfcab9cf4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
por: Anniina Färkkilä, et al.
Publicado: (2020) -
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
por: Panagiotis A. Konstantinopoulos, et al.
Publicado: (2021) -
Immunogenomic engineering of a plug-and-(dis)play hybridoma platform
por: Mark Pogson, et al.
Publicado: (2016) -
Immunogenomic Landscape Analysis of Prognostic Immune-Related Genes in Hepatocellular Carcinoma
por: Peng Qin, et al.
Publicado: (2021) -
Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories
por: Shinichi Mizuno, et al.
Publicado: (2021)